US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Ultragenyx Pharmaceutical Inc (RARE)
Ultragenyx Pharmaceutical Inc (RARE) ニュース

RARE

Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:RARE

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/15	06 : 11	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/14	09 : 49	GlobeNewswire Inc.	Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/13	08 : 47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/13	06 : 20	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/13	06 : 10	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/13	05 : 05	GlobeNewswire Inc.	Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/13	05 : 04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/13	05 : 00	GlobeNewswire Inc.	Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/12	06 : 47	GlobeNewswire Inc.	Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/11	08 : 58	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/11	06 : 20	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/05	05 : 05	GlobeNewswire Inc.	Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/05/31	05 : 04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/05/31	05 : 00	GlobeNewswire Inc.	Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/05/18	05 : 30	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/05/08	05 : 30	GlobeNewswire Inc.	Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/05/03	05 : 00	GlobeNewswire Inc.	Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/05/01	05 : 00	GlobeNewswire Inc.	Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/04/30	21 : 00	GlobeNewswire Inc.	Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/04/26	05 : 30	GlobeNewswire Inc.	Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/04/20	05 : 30	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/04/15	20 : 00	GlobeNewswire Inc.	Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/04/13	05 : 22	GlobeNewswire Inc.	Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/04/12	21 : 00	GlobeNewswire Inc.	Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/03/23	05 : 00	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/03/06	10 : 23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/03/06	10 : 22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/03/06	10 : 17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/03/06	10 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/03/06	10 : 13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc

Showing the most relevant articles for your search:NASDAQ:RARE

1 2 3 4 5 6 7 8 9 10 次へ >>

American Express

Financial Select Sector

Invesco QQQ Trust Series 1

BNP Paribas (QX)

US Dollar vs Yen

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約